Evidence map›Paper›PMID 42706605›Full record

ArticleCancer medicine2026

Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Jinguan Lin, Song Qu, Kunyu Yang, Tao Zhang, Yuansong Bai, Jian Wu, Yanjing Huang, Meiyu Fang, Xianling Liu, Xiaoming Huang and 18 more

Registry-linked trialAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05552807 (A Multicenter, Open Phase Ib Study to Evaluate the Efficacy and Safety of SCT-I10A in Combination With SCT200 or SCT200 in Combination With Paclitaxel/Docetaxel in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05552807 phase1unknown statusnot on this map

A Multicenter, Open Phase Ib Study to Evaluate the Efficacy and Safety of SCT-I10A in Combination With SCT200 or SCT200 in Combination With Paclitaxel/Docetaxel in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

TypeinterventionalSponsorSinocelltech Ltd.Ran2022 to 2023Enrolled120ConditionsHead and Neck Squamous CarcinomaArmsSCT-I10A, SCT200, paclitaxel, docetaxel
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Jinguan LinThe Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.
Song QuGuangxi Medical University Cancer Hospital, Nanning, China.
Kunyu YangUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Tao ZhangThe First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yuansong BaiThe Third Bethune Hospital of Jilin University, Changchun, China.
Jian WuChongqing University Cancer Hospital, Chongqing, China.
Yanjing HuangHainan General Hospital, Haikou, China.
Meiyu FangZhejiang Cancer Hospital, Hangzhou, China.ORCID https://orcid.org/0000-0001-9369-3640
Xianling LiuThe Second Xiangya Hospital of Central South University, Changsha, China.
Xiaoming HuangSun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Nianyong ChenWest China Hospital, Sichuan University, Chengdu, China.
Zhendong LiLiaoning Cancer Hospital & Institute, Shenyang, China.
Weidong LiAffiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Songnan ZhangYanbian University Hospital, Yanji, China.ORCID https://orcid.org/0000-0002-1961-282X
Shurong ZhangBeijing Tongren Hospital Affiliated to Capital Medical University, Beijing, China.
Guangyuan HuTongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID https://orcid.org/0000-0002-8060-4917
Yan SunPeking University Cancer Hospital, Beijing, China.
Xiaohong ChenBeijing Tongren Hospital Affiliated to Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-3825-2647
Yanyan LiuHenan Cancer Hospital, Zhengzhou, China.
Shanghua JingThe Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Liangfang ShenXiangya Hospital of Central South University, Changsha, China.
Zhiwei ChangThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Liangzhi XieBeijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China.ORCID https://orcid.org/0000-0003-4504-7622
Wenlin GaiBeijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China.
Yan WangBeijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China.
Xinyue ChenBeijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China.ORCID https://orcid.org/0009-0002-8271-0921
Dongfang LiuBeijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China.
Ye GuoShanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID https://orcid.org/0000-0002-1813-9815

Funding

the National Science and Technology Major Projects of China 2019ZX09732-001
6 · The paper itself

Abstract

backgroundEffective treatment options remain limited for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), including patients who have progressed after platinum-based chemotherapy and systemic-therapy-naïve patients. This Phase Ib trial evaluates the efficacy and safety of finotonlimab, a PD-1 antibody, combined with SCT200, an EGFR antibody.

methodsThis prospective, multicenter, open-label study enrolled patients into two cohorts: Cohort A (previously treated with platinum-based chemotherapy and immune checkpoint inhibitors) and Cohort B (systemic therapy-naïve). Patients received finotonlimab (200 mg every 3 weeks) and SCT200 (6 mg/kg weekly for 12 weeks, then 8 mg/kg every 2 weeks). The primary endpoint was objective response rate (ORR).

resultsAmong 41 patients, Cohort A (n = 11) showed an ORR of 27.3%, median progression-free survival (PFS) of 5.8 months, and median overall survival (OS) of 10.6 months. Cohort B (n = 30) had an ORR of 56.7%, median PFS of 9.6 months, and an estimated median OS of 13.6 months. Common treatment-related adverse events included hypomagnesemia (63.4%), rash (41.5%), and acneiform dermatitis (36.6%), which were manageable.

conclusionsThe combination of finotonlimab and SCT200 demonstrates promising efficacy, particularly in systemic therapy-naïve patients, warranting further investigation.

trial registrationClinicalTrials.gov identifier: NCT05552807; Chinadrugtrials.org.cn identifier: CTR20220917.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHead and Neck NeoplasmsNeoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and NeckAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesAntibodies, Monoclonal, Humanizedcombination therapyepidermal growth factor receptorimmunotherapyrecurrent or metastatic head and neck squamous cell carcinoma

Identifiers

PMID42706605
PMCPMC13550516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.